Skip to main content
Egyptian Liver Journal

Table 3 Comparison between pre-treatment and post-treatment lipid profile and Lp-PLA2 in patients who achieved SVR (n = 86)

From: The effect of hepatitis C virologic clearance on cardiovascular disease biomarker lipoprotein-associated phospholipase A2 and its relation to serum lipids

Lipid parameter

Time

Paired t-test

Pre-treatment

12 weeks post-treatment

t

p

LDL (mg/dl)

71.977 ± 24.126 (26–130)

103.244 ± 46.570 (44–203)

−9.395

<0.001

Total cholesterol (mg/dl)

170 ± 40.344 (80–278)

195.663 ± 55.678 (92–311)

−8.764

<0.001

HDL (mg/dl)

48.43 ± 6.785 (31–60)

53.907 ± 8.674 (37–71)

−10.1

<0.001

Lp-PLA2 (ng/ml)

322.372 ± 79.146 (189–498)

263.791 ± 51.804 (166–412)

13.829

<0.001

  1. Abbreviations: n, number; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2
Back to article page